Scarica l'app Stockscreener
100.61
2.35%
2.31
Dopo l'orario di chiusura:
101.00
0.39
+0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com India
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals global controller sells $65,800 in stock - Investing.com
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan - Kalkine Media
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan - Kalkine Media
Mirum Pharma (NASDAQ: MIRM) exec sells 658 shares under preset plan - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO trades 30,000 shares under preset plan - Stock Titan
Officer who sold $4M of Mirum (NASDAQ: MIRM) stock plans another sale - Stock Titan
Five investor conferences are on Mirum’s September schedule - Stock Titan
Mirum (NASDAQ: MIRM) investor plans Sept. stock sale after 40,000 shares sold - Stock Titan
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Mirum Pharmaceuticals Inc (08D) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc (08D) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc. (MIRM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citizens reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Mirum Pharmaceuticals(MIRM.US) Officer Sells US$4 Million in Common Stock - Moomoo
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals SVP, Global Controller Sold Shares Worth Over $4M - TradingView
Mirum Pharmaceuticals (MIRM) SVP exercises 40k options, sells shares - Stock Titan
Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale - Stock Titan
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Rice Hall James & Associates LLC Acquires New Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
TimesSquare Capital Management LLC Invests $43 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript - AOL.com
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative? - simplywall.st
Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell - MarketBeat
Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next - Yahoo Finance
Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management - Stock Titan
Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News - webull.com
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The National Law Review
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 6,001 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (MIRM) CFO sells 6,001 shares in Rule 10b5-1 trade - Stock Titan
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares - Investing.com
Mirum Pharmaceuticals (MIRM) CEO trades 20,000 shares after option exercise under 10b5-1 plan - Stock Titan
(MIRM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MIRM (MIRM) insider files to sell 6,001 shares after recent stock sales - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):